Product analysis: the valve remains implanted therefore no product analysis can be performed.Conclusion: without return of the product, no definitive conclusion can be made regarding the clinical observation.If information is provided in the future, a supplemental report will be issued.
|
Additional information was received that the patient had annular calcification but no left ventricular outflow tract (lvot) calcific ation.The valve was attempted to be deployed, was recaptured once and then deployed on the second attempt.The valve was intentionally implanted high at a depth of 2-3 millimeter (mm) due to the excessive calcification.The implanting physician determined that du e to the amount of calcium, a second valve was needed for additional radial force.Additionally, the high position of the valve resulted in a severe paravalvular leak (pvl).A post-implant balloon aortic valvuloplasty (bav) was performed with 25 mm non-medtronic (z med) balloon prior to implanting the second valve.The bav did not change the severity of the pvl, therefore a second transcatheter bioprosthetic valve was implanted.Following the implant of the second valve, the pvl had reduced to trace.No additional adverse patient effects were reported. updated data: b.5 - description of the event.H.6 - patient and device codes.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|